GW Pharma

Cannabis Industry & Marijuana Business Briefs Europe Cannabis Industry & Marijuana Business News GW Pharma GW Pharmaceuticals International Marijuana Business News United Kingdom

GW Pharma expects fiscal 2020 sales to reach $526 million

United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth quarter net sales will be approximately $148…

Canadian Medical Marijuana & Cannabis Industry News Cannabis Industry & Marijuana Business Briefs cannabis lawsuit Canopy Growth cbd CO2 extraction Epidiolex Europe Cannabis Industry & Marijuana Business News GW Pharma GW Pharmaceuticals intellectual property International Marijuana Business News marijuana intellectual property Marijuana Legalization and Regulatory News for Cannabis Businesses Medical Cannabis Industry & Recreational Marijuana Business News U.S. District Court United States Cannabis Industry & Marijuana Business News

Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement

Canadian cannabis producer Canopy Growth Corp. is suing Britain’s GW Pharmaceuticals in U.S. federal court, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW uses a Canopy-patented method to extract the CBD th…

Cannabis Industry & Marijuana Business Briefs Europe Cannabis Industry & Marijuana Business News GW Pharma GW Pharmaceuticals International Marijuana Business News United Kingdom

Epidiolex maker GW reports record quarterly revenue of $137 million

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by sales of its cannabidiol medicine Epidiolex in the United States. GW’s total revenue for the third quarter reached $137.1 million, abou…